Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
12-2013 | 12-2012 | 12-2011 | 12-2010 | 12-2009 | |
Sales | 23,113,100 | 22,603,400 | 24,286,500 | 23,076,000 | 21,836,000 |
Cost of Goods | 4,908,100 | 4,796,500 | 5,067,900 | 4,366,200 | 4,247,000 |
Gross Profit | 18,205,000 | 17,806,900 | 19,218,600 | 18,709,800 | 17,589,000 |
Operating Expenses | 12,834,700 | 13,073,200 | 13,691,000 | 12,179,800 | 12,001,700 |
Operating Income | 5,370,400 | 4,734,201 | 5,528,500 | 6,530,199 | 5,587,300 |
Other Income | 518,900 | 673,999 | -179,000 | -4,999 | -229,500 |
Pre-tax Income | 5,889,300 | 5,408,200 | 5,349,500 | 6,525,200 | 5,357,800 |
Income Tax | 1,204,500 | 1,319,600 | 1,001,800 | 1,455,700 | 1,029,000 |
Net Income Continuous | 4,684,800 | 4,088,600 | 4,347,700 | 5,069,500 | 4,328,800 |
Net Income | $4,684,800 | $4,088,600 | $4,347,700 | $5,069,500 | $4,328,800 |
EPS Basic Total Ops | 4.33 | 3.67 | 3.90 | 4.58 | 3.94 |
EPS Basic Continuous Ops | 4.33 | 3.67 | 3.90 | 4.58 | 3.94 |
EPS Diluted Total Ops | 4.32 | 3.66 | 3.90 | 4.58 | 3.94 |
EPS Diluted Continuous Ops | 4.32 | 3.66 | 3.90 | 4.58 | 3.94 |
EBITDA(a) | $6,816,000 | $6,196,401 | $6,902,100 | $7,858,399 | $6,885,100 |